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Target population in Spain is estimated at 500,000 patients and
15% of those receive a monoterapia drug treatment for acute
bipolar mania. Nowadays, when considering drug costs, direct
medical costs and adverse events treatment, average annual cost
per treated patient in Spain is estimated at €4006 and it is likely
to be estimated at €4039 after the introduction of ziprasidone.
Sensibility analysis showed that at a constant market share of
24% for the forecasted three years, then the introduction of
ziprasidone is not likely to have any economic impact on the
Spanish National Pharmaceutical budget. CONCLUSIONS:
This budget impact model shows that the introduction of ziprasi-
done is likely to have minimal impact on acute bipolar mania
medication costs in Spain. Current drug costs due to acute
bipolar mania were estimated at €908 millions for the next 3
years and at €916 millions after the introduction of ziprasidone.
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ADHD is a common disorder of childhood and adolescence in
the US and Europe. The NIMH MTA Study is a clinical land-
mark trial, including 579 children age 7–9.9 years with ADHD
according to DSM-IV criteria, who were randomly assigned to
14 months of medication management (MedMgt), intense behav-
ioral treatment (Beh), both combined (Comb), or community care
(CC). OBJECTIVE: To evaluate the cost-effectiveness of clinically
proven treatment strategies (neither placebo nor single drugs) for
ADHD and Hyperkinetic Disorder (HKD/HKCD, a subgroup
meeting ICD-10-based diagnostic criteria used in Europe) in ﬁve
countries, using patient-level data from the MTA Study over 14
months. METHODS: Medical resource utilization data came
from the MTA, excluding its research component. Unit costs (year
2005) were calculated from a societal and from a third-party
payer’s perspective for Germany, The Netherlands, Sweden, UK,
and USA. Corresponding to the primary study endpoint, treat-
ment response was deﬁned as normalization of core symptoms
(SNAP-IV teacher/parent scores <1). Utility estimates were
derived from expert estimates and parent-proxy-ratings.
RESULTS: Incremental cost-effectiveness ratios (ICERs) were
determined for the total study population and subgroups with
pure ADHD (without comorbidity, n = 184), pure HKD (n = 77),
or HKD/HKCD (n = 145). ICERs per additional patient “nor-
malized” ranged from to dominance to €4200 for MedMgt versus
CC and from €21,000 to €100,000 for Comb versus MedMgt.
MedMgt dominated Beh and exhibited extended dominance over
CC compared to a hypothetical “Do Nothing” alternative.
Results were supported by cost-effectiveness acceptability and
sensitivity analyses. CONCLUSIONS: Despite international dif-
ferences regarding standards of care, diagnostic criteria, and unit
costs, key ﬁndings for European jurisdictions were consistent with
US results. Although cost-utility estimates for this pediatric pop-
ulation should be interpreted with caution, results indicate accept-
able to attractive cost-effectiveness of an intense MedMgt
strategy. Further analyses will have to explore the impact of psy-
chiatric comorbidity and broader clinical endpoints.
PMH10
FUNCTIONAL IMPAIRMENT OF PATIENTS WITH ATTENTION-
DEFICIT/HYPERACTIVITY DISORDER (ADHD): AN
ALTERNATIVE COST-EFFECTIVENESS ANALYSIS OF
CLINICALLY PROVEN TREATMENT STRATEGIES BASED UPON
THE NIMH MTA STUDY
Schlander M1, Schwarz O1, Hakkaart-van Roijen L2, Jensen PS3,
Persson U4, Santosh PJ5,Trott GE6, MTA Cooperative Group O7
1Institute for Innovation & Valuation in Health Care (InnoVal-HC),
Eschborn, Germany, 2Institute for Medical Technology Assessment
(iMTA), Rotterdam,The Netherlands, 3Columbia University, New York,
NY, USA, 4The Swedish Institute for Health conomics, IHE, Lund,
Sweden, 5Institute of Child Health—Great Ormond Street Hospital,
London, UK, 6University of Wuerzburg, Aschaffenburg, Germany,
7National Institutes of Mental Health, Bethesda, MD, USA
Beyond disease-deﬁning core symptoms of inattention, hyperac-
tivity, and impulsivity, ADHD is characterized by functional
impairment of patients. The Columbia Impairment Scale (CIS) is
a parent rating scale with relatively strong psychometric prop-
erties, tapping four major dimensions: interpersonal relations,
psychopathology, schoolwork, and use of leisure time. OBJEC-
TIVES: CIS ratings from the NIMH MTA Study (n = 579 chil-
dren with ADHD according to DSM-IV-criteria) were used as an
alternative outcome measure to evaluate the cost-effectiveness of
medication management (MedMgt), intense behavioral treat-
ment (Beh), both combined (Comb), or community care (CC) in
the study population and in three subgroups: hyperkinetic dis-
order (according to ICD-10-criteria preferred in Europe); pure
HKD or HKD/HKCD, and in pure ADHD, over 14 months.
METHODS: For costing (societal and third-party payer’s per-
spectives), patient-level resource utilization data were combined
with country-speciﬁc unit costs for Germany, The Netherlands,
Sweden, UK, and United States (year 2005). Incremental cost-
effectiveness ratios (ICERs) were determined using functional
improvement (CIS effect size [ES], Cohen’s d) as clinical outcome
criterion. Four treatment strategies and a hypothetical “Do
Nothing” alternative were compared with each other. RESULTS:
The four MTA treatment strategies were all clinically effective.
Across jurisdictions, both CC versus “Do Nothing” (ICERs
ranging from €1200/ES to €2600/ES) and MedMgt (ICERs
versus “Do Nothing” from €1000/ES to €2700/ES, ICERs versus
CC from dominance to €3000/ES) appeared attractive on
grounds of cost-effectiveness. MedMgt dominated Beh, and
ICERs for Comb versus MedMgt ranged from €500,000/ES to
€1,000,000/ES. Results for subgroups with pure ADHD,
HKD/HKCD, and pure HKD were broadly similar. Sensitivity
analyses including probabilistic evaluations using non-paramet-
ric bootstrapping supported these ﬁndings. CONCLUSIONS:
Despite notable international differences in terms of diagnostic
criteria, standards of care, and unit costs, the cost-effectiveness
of MTA-based clinical treatment strategies for patients with pure
ADHD seemed remarkably similar across jurisdictions. The
impact of comorbidity remains to be explored.
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OBJECTIVE: In light of recent clinical evidence, the indication
of the NMDA antagonist memantine has been extended to
“moderate to severe Alzheimer’s disease (AD)”. No pharmaco-
economic evaluation has been performed in this indication to
